Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty generic drugs, according to a new interim staff report. FTC said the "Big 3 PBMs" -- CVS's Caremark, Cigna's Express Scripts, and UnitedHealth's OptumRx -- imposed markups of hundreds to thousands of percent on critical drugs, including those for cancer and HIV, between 2017 and 2022.